Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in...

Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer ( Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA )

Next generation inhibitors help overcome problems of resistance in ALK positive...

Dr Ross Camidge - University of Colorado, Denver, USA

Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer ( Dr Ross Camidge - University of Colorado, Denver, USA )

Transarterial chemoembolization with or without sorafenib for intermediate...

Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an...

Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma ( Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China )

Phase III study finds initial nivolumab-based treatment halts melanoma...

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase III study finds initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin...

Dr Merry-Jennifer Markham - University of Florida, Florida, USA

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple...

Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )

Ibrutinib combination regimen shows substantial benefits in relapsed CLL

Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

Ibrutinib combination regimen shows substantial benefits in relapsed CLL ( Dr Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrozole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA

Effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA )

Novel JAK inhibitor pacritinib proving effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

More from ecancer